Genmab Financials

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GA</div>
GMAB -- Denmark Stock  

DKK 2,028  53.00  2.68%

Understanding current and past Genmab AS Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. We strongly advise to harness Genmab AS fundamental analysis to see if markets are presently mispricing the organization. Simply put, you can make use of it to find out if Genmab AS is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found twenty-five available reported financial drivers for Genmab AS, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Genmab AS financials, including its Price to Sales, Gross Profit and the relationship between Price to Book and Revenue . Use Genmab AS to enhance returns of your portfolios. The stock experiences unexpected upward trend. Watch out for market signals. Check odds of Genmab AS to be traded at kr2433.6 in 30 days.

Search Fundamentals

With this module, you can analyze Genmab financials for your investing period. You should be able to track the changes in Genmab AS individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Chance of Financial Distress

Genmab AS has less than 37 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of ods of distress for Genmab AS stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info

Genmab AS Company Summary

Genmab AS, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark.
Foreign Associate  USA
InstrumentDenmark Stock View All
ExchangeCopenhagen Stock Exchange
Business AddressKalvebod Brygge 43
Phone45 70 20 27 28
CurrencyDKK - Danish Krone

Genmab AS Key Financial Ratios

Genmab Financial Ratios Relationships

Genmab AS is one of the top stocks in shares outstanding category among related companies. It is rated as one of the top companies in current valuation category among related companies reporting about  1,420  of Current Valuation per Shares Outstanding.

Genmab AS Systematic Risk

The output start index for this execution was sixteen with a total number of output elements of fourty-five. The Beta measures systematic risk based on how returns on Genmab AS correlated with the market. If Beta is less than 0 Genmab AS generally moves in the opposite direction as compared to the market. If Genmab AS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genmab AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genmab AS is generally in the same direction as the market. If Beta > 1 Genmab AS moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Genmab AS Financials

What exactly are Genmab AS Financials? Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Genmab AS income statement, its balance sheet, and the statement of cash flows. Potential Genmab AS investors and stakeholders use the financial statements to determine how well the company is positioned to perform in the future. Although Genmab AS investors may use each financial statement separately, they are all related. The changes in Genmab AS's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Genmab AS's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Genmab AS Thematic Clasifications

Healthcare Idea

Genmab AS May 25, 2020 Opportunity Range

Please check Risk vs Return Analysis. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page